Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%
  • Tue, 23-May-2023
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics’ New mAbs Facility Receives EU GMP Certification for bBevacizumab
  • Fri, 28-Apr-2023
  • Posted by: Biocon Biologics
No Comments

Serum & Biocon Biologics Agree to Restructure Equity Investment
  • Tue, 25-Apr-2023
  • Posted by: Biocon Biologics
No Comments

Biocon Awarded a Silver Medal by EcoVadis for its Sustainability Accomplishments
  • Mon, 03-Apr-2023
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Wins the ‘ABEA : Bioprocessing Excellence in South Asia’ Award
  • Tue, 28-Mar-2023
  • Posted by: Biocon Biologics
No Comments

Biocon Q3FY23 Revenue at Rs 3,020 Cr, Up 36%; Biosimilars Up 54%; Research Services Up 23%; Generics Up 18%
  • Thu, 09-Mar-2023
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual ‘Great Managers Award 2022’
  • Thu, 22-Dec-2022
  • Posted by: Biocon Biologics
No Comments

Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited
  • Mon, 05-Dec-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Biologics Completes Acquisition of Viatris’ Global Biosimilars Business
  • Tue, 29-Nov-2022
  • Posted by: Biocon Biologics
No Comments

Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% Gross R&D Spend at Rs 252 Crore, Up 52%
  • Tue, 15-Nov-2022
  • Posted by: Biocon Biologics
No Comments
Report adverse event/ side effects and/or product complaints for Biocon Biologics products.

* Cookie Notice | Privacy Policy | Terms of Use © 2023, Biocon Biologics Limited (a Subsidiary of Biocon Limited). All Rights Reserved
Share